RU2010147000A - Предназначенная для перорального применения фармацевтическая композиция - Google Patents
Предназначенная для перорального применения фармацевтическая композиция Download PDFInfo
- Publication number
- RU2010147000A RU2010147000A RU2010147000/15A RU2010147000A RU2010147000A RU 2010147000 A RU2010147000 A RU 2010147000A RU 2010147000/15 A RU2010147000/15 A RU 2010147000/15A RU 2010147000 A RU2010147000 A RU 2010147000A RU 2010147000 A RU2010147000 A RU 2010147000A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- mannitol
- receptor agonist
- octylphenyl
- propan
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 35
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 16
- 229930195725 Mannitol Natural products 0.000 claims abstract 16
- 239000000594 mannitol Substances 0.000 claims abstract 16
- 235000010355 mannitol Nutrition 0.000 claims abstract 16
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims abstract 13
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims abstract 13
- 239000000018 receptor agonist Substances 0.000 claims abstract 13
- 229940044601 receptor agonist Drugs 0.000 claims abstract 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract 4
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical group CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims abstract 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000002245 particle Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000000811 xylitol Substances 0.000 claims abstract 4
- 235000010447 xylitol Nutrition 0.000 claims abstract 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract 4
- 229960002675 xylitol Drugs 0.000 claims abstract 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 2
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical group Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 claims abstract 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract 2
- 229960000367 inositol Drugs 0.000 claims abstract 2
- 239000000832 lactitol Substances 0.000 claims abstract 2
- 235000010448 lactitol Nutrition 0.000 claims abstract 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract 2
- 229960003451 lactitol Drugs 0.000 claims abstract 2
- 229960001855 mannitol Drugs 0.000 claims abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000010452 phosphate Substances 0.000 claims abstract 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000004513 sizing Methods 0.000 claims abstract 2
- 239000007909 solid dosage form Substances 0.000 claims abstract 2
- 239000007921 spray Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010047470 viral myocarditis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Фармацевтическая композиция, пригодная для перорального введения, которая содержит: ! (а) агонист рецептора S1P; и ! (б) маннит, ! причем эта композиция представляет собой твердую дозированную форму, маннит приготавливают из высушенной распылением композиции или обладает большой площадью специфической поверхности, а агонист рецептора S1P выбирают из 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диола (FTY720), его фармацевтически приемлемой соли и РТY720-фосфата. ! 2. Композиция по п.1, в которой агонист рецептора S1P представляет собой 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диол или его фармацевтически приемлемые соли. ! 3. Композиция по п.1, в которой агонист рецептора S1P представляет собой гидрохлорид 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диола. ! 4. Композиция по любому из предшествующих пунктов, в которой маннит приготавливают из высушенной распылением композиции. ! 5. Композиция п.1 или 2, в которой маннит имеет средний размер частиц от 100 до 300 мкм или от 150 до 250 мкм. ! 6. Композиция п.1 или 2, в которой маннит имеет насыпную плотность от 0,4 до 0,6 г/мл или от 0,45 до 0,55 г/мл. ! 7. Композиция п.1 или 2, в которой маннит имеет удельную поверхность одной частицы от 1 до 7 м2/г. ! 8. Композиция п.1 или 2, в которой композиция дополнительно включает маннит, инозит, ксилит или лактит, например дополнительно включает ксилит. ! 9. Композиция п.1 или 2, в которой агонист рецептора S1P является измельченным и/или является предварительно просеянным. ! 10. Композиция п.1 или 2, дополнительно содержащая замасливатель. ! 11. Композиция по п.10, содержащая от 0,01 до 20 мас.% агониста рецептора S1P. ! 12. Композиция п.1 или 2, содержащая от 90 до 99,5 мас.% маннита. ! 13. Композиция п.1 или 2, где ко
Claims (15)
1. Фармацевтическая композиция, пригодная для перорального введения, которая содержит:
(а) агонист рецептора S1P; и
(б) маннит,
причем эта композиция представляет собой твердую дозированную форму, маннит приготавливают из высушенной распылением композиции или обладает большой площадью специфической поверхности, а агонист рецептора S1P выбирают из 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диола (FTY720), его фармацевтически приемлемой соли и РТY720-фосфата.
2. Композиция по п.1, в которой агонист рецептора S1P представляет собой 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диол или его фармацевтически приемлемые соли.
3. Композиция по п.1, в которой агонист рецептора S1P представляет собой гидрохлорид 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диола.
4. Композиция по любому из предшествующих пунктов, в которой маннит приготавливают из высушенной распылением композиции.
5. Композиция п.1 или 2, в которой маннит имеет средний размер частиц от 100 до 300 мкм или от 150 до 250 мкм.
6. Композиция п.1 или 2, в которой маннит имеет насыпную плотность от 0,4 до 0,6 г/мл или от 0,45 до 0,55 г/мл.
7. Композиция п.1 или 2, в которой маннит имеет удельную поверхность одной частицы от 1 до 7 м2/г.
8. Композиция п.1 или 2, в которой композиция дополнительно включает маннит, инозит, ксилит или лактит, например дополнительно включает ксилит.
9. Композиция п.1 или 2, в которой агонист рецептора S1P является измельченным и/или является предварительно просеянным.
10. Композиция п.1 или 2, дополнительно содержащая замасливатель.
11. Композиция по п.10, содержащая от 0,01 до 20 мас.% агониста рецептора S1P.
12. Композиция п.1 или 2, содержащая от 90 до 99,5 мас.% маннита.
13. Композиция п.1 или 2, где композиция представляет собой единичную дозированную форму и содержит 0,5 до 10 мг агониста рецептора S1P.
14. Композиция п.1 или 2, используемая в способе лечения и предупреждения отторжения трансплантата органа или ткани, или лечения аутоиммунного заболевания или воспалительных состояний, вирусного миокардита или вирусных заболеваний, связанных с вирусным миокардитом, или рассеянного склероза.
15. Композиция по п.14, используемая в способе лечения рассеянного склероза.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46121503P | 2003-04-08 | 2003-04-08 | |
| US60/461,215 | 2003-04-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009105403/15A Division RU2009105403A (ru) | 2003-04-08 | 2009-02-17 | Твердая фармацевтическая композиция для перорального введения (варианты) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012148593/15A Division RU2012148593A (ru) | 2003-04-08 | 2012-11-15 | Предназначенная для перорального применения фармацевтическая композиция |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010147000A true RU2010147000A (ru) | 2012-08-10 |
| RU2475237C2 RU2475237C2 (ru) | 2013-02-20 |
Family
ID=32326722
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005134173/15A RU2358716C2 (ru) | 2003-04-08 | 2004-04-06 | Органические соединения |
| RU2009105403/15A RU2009105403A (ru) | 2003-04-08 | 2009-02-17 | Твердая фармацевтическая композиция для перорального введения (варианты) |
| RU2010146697/15A RU2475236C2 (ru) | 2003-04-08 | 2010-11-17 | Способ получения фармацевтической композиции |
| RU2010147000/15A RU2475237C2 (ru) | 2003-04-08 | 2010-11-18 | Предназначенная для перорального применения фармацевтическая композиция |
| RU2012148593/15A RU2012148593A (ru) | 2003-04-08 | 2012-11-15 | Предназначенная для перорального применения фармацевтическая композиция |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005134173/15A RU2358716C2 (ru) | 2003-04-08 | 2004-04-06 | Органические соединения |
| RU2009105403/15A RU2009105403A (ru) | 2003-04-08 | 2009-02-17 | Твердая фармацевтическая композиция для перорального введения (варианты) |
| RU2010146697/15A RU2475236C2 (ru) | 2003-04-08 | 2010-11-17 | Способ получения фармацевтической композиции |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012148593/15A RU2012148593A (ru) | 2003-04-08 | 2012-11-15 | Предназначенная для перорального применения фармацевтическая композиция |
Country Status (41)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1773307E (pt) * | 2004-07-30 | 2015-01-14 | Novartis Ag | Formulações de compostos à base de 2-amino-1,3- propanodiol |
| CN1891212B (zh) * | 2005-07-07 | 2010-10-13 | 马启明 | 一种口服制剂及其制备方法 |
| PL2295049T3 (pl) * | 2005-09-09 | 2015-04-30 | Novartis Ag | Leczenie chorób autoimmunologicznych |
| LT2623113T (lt) | 2005-11-09 | 2017-07-10 | Onyx Therapeutics, Inc. | Junginiai, skirti fermentų slopinimui |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| PL2041158T3 (pl) | 2006-06-19 | 2013-08-30 | Onyx Therapeutics Inc | Peptydowe epoksyketony do hamowania proteasomu |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| EP1923054A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator |
| AU2011235934A1 (en) * | 2006-09-26 | 2011-11-03 | Novartis Ag | Pharmaceutical compositions comprising an S1P modulator |
| EP1923058A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Coated pharmaceutical composition comprising an S1P agonist or modulator |
| EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
| EP1923055A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator |
| RU2487703C2 (ru) * | 2006-09-26 | 2013-07-20 | Новартис Аг | Фармацевтические композиции, включающие модулятор s1р |
| WO2008124210A1 (en) * | 2007-02-14 | 2008-10-16 | Emory University | Methods and compositions for treating or preventing infection using leukocyte sequestration agents |
| PL2140867T5 (pl) | 2007-03-29 | 2023-10-30 | Daiichi Sankyo Company, Limited | Kompozycja farmaceutyczna |
| ES2684340T3 (es) | 2007-10-04 | 2018-10-02 | Onyx Therapeutics, Inc. | Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos |
| WO2009048993A2 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| AU2012216630B2 (en) * | 2007-10-12 | 2015-01-22 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators |
| JP5534645B2 (ja) * | 2008-01-11 | 2014-07-02 | 日医工株式会社 | 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤 |
| JP5452237B2 (ja) | 2008-02-07 | 2014-03-26 | 杏林製薬株式会社 | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
| HRP20170246T4 (hr) | 2008-03-17 | 2020-02-07 | Actelion Pharmaceuticals Ltd. | Režim doziranja za selektivni agonist s1p1-receptora |
| US11166917B2 (en) * | 2008-06-20 | 2021-11-09 | Merck Patent Gmbh | Direct injection moldable and rapidly disintegrating tablet matrix |
| BRPI0914139A2 (pt) | 2008-06-20 | 2015-10-20 | Novartis Ag | composições pediátricas para o tratamento de esclerose múltipla |
| RU2498636C2 (ru) * | 2008-09-04 | 2013-11-20 | Карджилл Инкорпорейтед | Таблетирование эритрита |
| EP2349313A4 (en) | 2008-10-21 | 2012-08-29 | Onyx Therapeutics Inc | COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES |
| AU2013100532B4 (en) * | 2008-11-11 | 2013-11-28 | Novartis Ag | Crystalline forms of fingolimod HCL |
| KR101393994B1 (ko) * | 2008-11-11 | 2014-05-14 | 노파르티스 아게 | 핑골리모드 ｈｃｌ의 결정질 형태 |
| RU2543621C2 (ru) | 2008-11-11 | 2015-03-10 | Новартис Аг | Соли финголимода |
| JP5305421B2 (ja) | 2008-12-17 | 2013-10-02 | 第一三共株式会社 | ジアミン誘導体の製造方法 |
| WO2010082531A1 (ja) | 2009-01-13 | 2010-07-22 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
| JP5666424B2 (ja) | 2009-03-10 | 2015-02-12 | 第一三共株式会社 | ジアミン誘導体の製造方法 |
| EP2407450B1 (en) | 2009-03-13 | 2015-04-22 | Daiichi Sankyo Company, Limited | Method for producing optically active diamine derivative |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| ES2605034T3 (es) * | 2009-06-18 | 2017-03-10 | Daiichi Sankyo Company, Limited | Composición farmacéutica con solubilidad mejorada |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| EA201290844A1 (ru) | 2010-03-01 | 2013-03-29 | Оникс Терапьютикс, Инк. | Соединения для ингибирования иммунопротеасом |
| JP5692873B2 (ja) | 2010-03-19 | 2015-04-01 | 第一三共株式会社 | ジアミン誘導体の結晶およびその製造方法 |
| CA2793525C (en) | 2010-03-19 | 2014-05-06 | Daiichi Sankyo Company, Limited | Method for improving dissolution of anticoagulant agent |
| CA2797029A1 (en) * | 2010-04-22 | 2011-10-27 | Ratiopharm Gmbh | A method of preparing an oral dosage form comprising fingolimod |
| JP5780657B2 (ja) | 2010-07-02 | 2015-09-16 | 第一三共株式会社 | 光学活性ジアミン誘導体の塩の製造方法 |
| WO2012070059A1 (en) | 2010-11-25 | 2012-05-31 | Shilpa Medicare Limited | Fingolimod polymorphs and their processes |
| PT2661261T (pt) | 2011-01-07 | 2019-10-25 | Novartis Ag | Formulações imunossupressoras. |
| EP2665471B1 (en) | 2011-01-19 | 2017-12-27 | Pathologica, LLC. | Controlled release oral pharmaceutical dosage forms comprising mgbg |
| AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| WO2013019872A1 (en) | 2011-08-01 | 2013-02-07 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutical compositions comprising fingolimod |
| ES2673182T3 (es) | 2011-08-10 | 2018-06-20 | Daiichi Sankyo Company, Limited | Composición farmacéutica que contiene un derivado de diamina |
| WO2013091704A1 (en) | 2011-12-22 | 2013-06-27 | Synthon Bv | Pharmaceutical composition comprising fingolimod |
| RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
| RU2506949C1 (ru) * | 2012-06-13 | 2014-02-20 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
| RU2496486C1 (ru) * | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| BR112015016189A8 (pt) | 2013-01-08 | 2019-10-22 | Pathologica Llc | usos de metilglioxal bis (guanilhidrazona) (mgbg), uso de metilglioxal bis (guanilhidrazona) (mgbg) e um agente e composição farmacêutica |
| WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
| WO2014175287A1 (ja) * | 2013-04-26 | 2014-10-30 | 国立大学法人 京都大学 | 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物 |
| ES2770500T3 (es) * | 2013-05-13 | 2020-07-01 | Synthon Bv | Composición farmacéutica que comprende fingolimod |
| US20160128951A1 (en) * | 2013-07-29 | 2016-05-12 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
| RU2530626C1 (ru) * | 2013-10-21 | 2014-10-10 | Ооо "Валента-Интеллект" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| CN106794159A (zh) * | 2014-08-22 | 2017-05-31 | 广东东阳光药业有限公司 | 一种芬戈莫德固体组合物及其制备方法 |
| WO2016042493A1 (en) * | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| AU2016209466A1 (en) * | 2015-01-20 | 2017-08-10 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| RU2577230C1 (ru) * | 2015-04-09 | 2016-03-10 | Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" | Способ получения капсул финголимода гидрохлорида |
| US9690975B2 (en) * | 2015-05-28 | 2017-06-27 | Axogen Corporation | Quantitative structural assay of a nerve graft |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| WO2018178744A1 (en) | 2017-03-29 | 2018-10-04 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
| GR1009654B (el) | 2018-08-31 | 2019-11-18 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| JP7503420B2 (ja) * | 2020-05-18 | 2024-06-20 | 東和薬品株式会社 | フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法 |
| EP4181906A1 (en) | 2020-07-16 | 2023-05-24 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection |
| MX2023008907A (es) * | 2021-01-28 | 2023-08-09 | Priothera Sas | Metodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p). |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7607683A (nl) * | 1976-07-12 | 1978-01-16 | Akzo Nv | Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan. |
| US4110332A (en) * | 1977-05-05 | 1978-08-29 | Chevron Research Company | 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones |
| US4559153A (en) | 1983-10-25 | 1985-12-17 | Phillips Petroleum Company | Metal working lubricant |
| US5112616A (en) | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| JP2841857B2 (ja) * | 1990-11-29 | 1998-12-24 | 田辺製薬株式会社 | 長期間安定な経口用医薬製剤 |
| ES2126658T3 (es) | 1992-10-21 | 1999-04-01 | Yoshitomi Pharmaceutical | Compuesto de 2-amino-1,3-propanodiol e inmunosupresor. |
| ES2171191T3 (es) | 1994-08-22 | 2002-09-01 | Mitsubishi Pharma Corp | Compuesto de benceno y uso medicinal del mismo. |
| SI0812588T1 (en) | 1995-12-28 | 2005-02-28 | Mitsubishi Pharma Corporation | Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder |
| JP2002241272A (ja) | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| DK0990440T3 (da) * | 1997-02-27 | 2009-02-23 | Novartis Ag | Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid |
| SI1002792T1 (en) * | 1997-04-04 | 2004-12-31 | Mitsubishi Pharma Corporation | 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP3545595B2 (ja) | 1998-04-01 | 2004-07-21 | 花王株式会社 | スフィンゴ糖脂質の製造法 |
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| WO2001003739A1 (fr) * | 1999-07-12 | 2001-01-18 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate |
| NZ523554A (en) | 2000-07-13 | 2004-12-24 | Sankyo Co | Amino alcohol derivatives |
| EP1315735A4 (en) | 2000-08-31 | 2005-04-06 | Merck & Co Inc | Phosphate derivatives as immunoregulatory compounds |
| US6953332B1 (en) | 2000-11-28 | 2005-10-11 | St. Jude Medical, Inc. | Mandrel for use in forming valved prostheses having polymer leaflets by dip coating |
| PL367348A1 (en) | 2001-03-26 | 2005-02-21 | Novartis Ag | 2-amino-propanol derivatives |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| EP1424078A4 (en) | 2001-09-04 | 2009-03-25 | Ono Pharmaceutical Co | RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT |
| CA2460640C (en) | 2001-09-27 | 2011-03-29 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same |
| CA2461212C (en) | 2001-09-27 | 2010-08-17 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same |
| EP1469863A2 (en) | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| AU2003214873A1 (en) | 2002-01-18 | 2003-09-02 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| WO2003062252A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| CN101884781B (zh) * | 2004-07-16 | 2012-07-18 | 杏林制药株式会社 | 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物 |
-
2004
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/en not_active Withdrawn
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/en not_active Revoked
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Ceased
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de not_active Ceased
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/en not_active Ceased
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko not_active Expired - Lifetime
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 CA CA2521325A patent/CA2521325C/en not_active Expired - Lifetime
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 CA CA2707750A patent/CA2707750A1/en not_active Abandoned
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Ceased
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 EP EP10186307A patent/EP2319502A1/en not_active Withdrawn
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 EP EP08161161A patent/EP2008650A3/en not_active Withdrawn
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 EP EP04725895A patent/EP1613288B1/en not_active Expired - Lifetime
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
-
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
-
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
-
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
-
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
-
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I2/el unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
-
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
-
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
-
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
-
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
-
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
-
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
-
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
-
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010147000A (ru) | Предназначенная для перорального применения фармацевтическая композиция | |
| JP2021035955A (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP2004307506A5 (ru) | ||
| JP5386173B2 (ja) | 閉経前の性的欲求障害の治療のためのフリバンセリンの使用 | |
| CN1607947A (zh) | 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物 | |
| EP1094814A2 (en) | Methods and compositions for increasing penetration of hiv protease inhibitors | |
| JP2007530620A5 (ru) | ||
| RU2562571C2 (ru) | Педиатрические композиции для лечения рассеянного склероза | |
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| WO2008151092A1 (en) | Methods and compositions for administration of oxybutynin | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| PL196479B1 (pl) | Zastosowanie saredutantu i jego farmaceutycznie dopuszczalnych soli do wytwarzania leków | |
| BG99167A (bg) | Фармацевтични състави за ректално приложение на адкилсулфонамиди- агонисти на 5-нт долу 1 | |
| EP1901714A2 (en) | Pharmaceutical dosage forms comprising escitalopram in form of granules | |
| CN1216598C (zh) | 药物用途 | |
| JPH03170475A (ja) | 抑うつ症治療剤 | |
| JP6093015B2 (ja) | 改良された流動性を有する医薬組成物、薬剤、並びに同一物を製造及び使用するための方法 | |
| US20120029047A1 (en) | Use of hdac inhibitors for the treatment of bone destruction | |
| KR20010105418A (ko) | 기분 장애 치료용 오사네턴트 | |
| JPH08504203A (ja) | パーキンソン病およびその進行を治療する薬剤の製造のためのイダゾキサンおよびその誘導体の使用 | |
| CN1293571A (zh) | 副作用降低的硫加宾延长释放制剂 | |
| JP2610735B2 (ja) | 抗鬱剤および抗ストレス剤組成物 | |
| JPH07324035A (ja) | 滑膜細胞増殖抑制剤及び慢性関節リウマチ治療剤 | |
| EP1010425A9 (en) | Remedies for irritable bowel syndrome | |
| KR20140038155A (ko) | 4-(5-(2-메톡시페닐)-3-(ｐ-톨릴)-4,5-디하이드로-1Ｈ-피라졸-1-일)-4-옥소부탄산을 포함하는 골대사성 질환의 예방 및 치료용 조성물 |